Quest Diagnostics income statement

In fiscal 2025, Quest Diagnostics reported revenue of $11.04bn, up 11.8% on the year before, operating income of $1.56bn (a 14.1% margin) and net income of $992m, or $8.75 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ billions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Quest Diagnostics: income statement, annual
Fiscal year	2009Dec 2009	2010Dec 2010	2011Dec 2011	2012Dec 2012	2013Dec 2013	2014Dec 2014	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMSept 2026
Revenue	7.5	7.3	7.4	7.4	7.1	7.4	7.5	7.2	7.4	7.5	7.7	9.4	10.8	9.9	9.3	9.9	11.0	11.8
Cost of revenue	4.3	4.3	4.4	4.4	4.3	4.6	4.7	4.6	4.7	4.9	5.0	5.8	6.6	6.5	6.2	6.6	7.4	7.9
Gross profit	3.1	3.1	3.0	3.0	2.8	2.8	2.8	2.9	2.7	2.6	2.7	3.6	4.2	3.4	3.1	3.2	3.7	3.9
Selling, general and administrative	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.4	1.4	1.4	1.5	1.6	1.7	1.9	1.6	1.8	2.0	2.1
Operating income	1.4	1.3	1.0	1.2	1.5	1.0	1.4	1.3	1.2	1.1	1.2	2.0	2.4	1.4	1.3	1.3	1.6	1.7
Interest expense	0.1	0.1	0.2	—	—	0.2	0.2	0.1	0.2	0.2	0.2	0.2	0.2	0.1	0.2	—	—	—
Net interest income	—	—	—	—	−0.2	−0.2	−0.2	−0.1	−0.2	−0.2	−0.2	−0.2	−0.2	−0.1	−0.2	−0.2	−0.3	−0.3
Income before tax	1.2	1.2	0.9	—	1.3	0.8	1.1	1.1	1.0	0.9	1.1	1.9	2.6	1.2	1.1	1.2	1.3	1.5
Income tax	0.5	0.4	0.4	0.4	0.5	0.3	0.4	0.4	0.2	0.2	0.2	0.5	0.6	0.3	0.2	0.3	0.3	0.3
Net income	0.7	0.7	0.5	0.6	0.8	0.6	0.7	0.6	0.8	0.7	0.9	1.4	2.0	0.9	0.9	0.9	1.0	1.1
Diluted EPS	$3.87	$4.05	$2.92	$3.46	$5.54	$3.81	$4.87	$4.51	$5.50	$5.29	$6.28	$10.47	$15.55	$7.97	$7.49	$7.69	$8.75	$10.06
Diluted shares (average)	188m	177m	160m	160m	153m	145m	145m	142m	140m	139m	136m	136m	128m	118m	113m	113m	113m	112m
EBITDA	1.6	1.5	1.3	1.5	1.8	1.3	1.7	1.5	1.4	1.4	1.6	2.3	2.8	1.9	1.7	1.8	2.1	2.3

US$ millions unless shown otherwise. Fiscal quarters.

Quest Diagnostics: income statement, quarterly
Quarter	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026	2026 Q3Sept 2026
Revenue	2,621	2,652	2,761	2,816	2,806	2,895	3,043	3,097
Cost of revenue	1,763	1,789	1,818	1,867	1,896	1,953	2,016	2,055
Gross profit	858	863	943	949	910	942	1,027	1,042
Selling, general and administrative	466	476	486	501	504	504	529	523
Operating income	361	346	438	386	386	399	459	479
Net interest income	−65	−67	−67	−66	−64	−63	−63	−61
Income before tax	299	276	384	328	330	334	412	416
Income tax	68	59	97	77	81	74	88	99
Net income	222	220	282	245	245	252	320	312
Diluted EPS	$1.95	$1.94	$2.47	$2.16	$2.18	$2.24	$2.84	$2.78
EBITDA	496	486	581	528	531	546	605	626

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: DGX vs DVA DGX vs LH BTSG vs DGX

More: Health Care Services stocks compared, Health Care sector, rankings of US companies

Figures from Quest Diagnostics's SEC filings (10-K and 10-Q), retrieved October 24, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Quest Diagnostics.